scholarly journals P1‐1: Role of early intrapleural fibrinolytic therapy for thoracic empyema: An analysis of the nationwide inpatient database

Respirology ◽  
2021 ◽  
Vol 26 (S3) ◽  
pp. 69-69
Keyword(s):  
Fibrinolytic Therapy ◽  
Thoracic Empyema ◽  
Inpatient Database

Role of Fibrinolytic Therapy in Empyema Thoracis – A Hospital Based one year Cross Sectional Study

2012 ◽  
Vol 2 (2) ◽  
pp. 345-350
Author(s):  
Dr. Girish.L Dandagi ◽  
◽  
Venkat kalyana kumar. P ◽  
Dr. Dr.Isaac Mathew ◽  
Dr. Dr.G S Gaude Dr. Dr.G S Gaude
Keyword(s):  
Cross Sectional Study ◽  
Fibrinolytic Therapy ◽  
Empyema Thoracis ◽  
Sectional Study ◽  
Cross Sectional ◽  
One Year

scholarly journals Malignant Pleural Effusions: Management Options

2018 ◽  
Vol 39 (06) ◽  
pp. 704-712 ◽  
Author(s):  
Jose Porcel ◽  
Najib Rahman ◽  
David McCracken
Keyword(s):  
Malignant Pleural Effusion ◽  
Conventional Treatment ◽  
Fibrinolytic Therapy ◽  
Patient Benefit ◽  
Management Options ◽  
Future Directions ◽  
Population Demographics ◽  
Health Care Burden ◽  
Significant Health

AbstractMalignant pleural effusion (MPE) represents advanced metastatic malignancy and is associated with poor median survival. Incidence remains high and continues to rise, in part due to changing population demographics. This therefore represents a significant health care burden. Management is predominantly palliative in nature and multiple interventions are available within conventional treatment paradigms, all of which are proven to result in statistically significant patient benefit. This article further explores the methods available in the management of MPE along with the pitfalls, complications, and alternatives. Recent advances within the field are discussed with an exploration of likely future directions, including the role of ultrasound as a prospective predictor and the role of intrapleural fibrinolytic therapy.

Improving adjunctive treatment in pulmonary embolism and fibrinolytic therapy. The role of enoxaparin and weight-adjusted unfractionated heparin

2008 ◽  
Vol 27 (2) ◽  
pp. 154-162 ◽  
Author(s):  
Carlos Jerjes-Sánchez ◽  
Sergio Villarreal-Umaña ◽  
Alicia Ramírez-Rivera ◽  
Anabel Garcia-Sosa ◽  
Luis Miguel-Canseco ◽  
...  
Keyword(s):  
Pulmonary Embolism ◽  
Unfractionated Heparin ◽  
Fibrinolytic Therapy ◽  
Adjunctive Treatment

scholarly journals Fibrin turnover and pleural organization: bench to bedside

2018 ◽  
Vol 314 (5) ◽  
pp. L757-L768 ◽  
Author(s):  
Andrey A. Komissarov ◽  
Najib Rahman ◽  
Y. C. Gary Lee ◽  
Galina Florova ◽  
Sreerama Shetty ◽  
...  
Keyword(s):  
Plasminogen Activator ◽  
Plasminogen Activator Inhibitor ◽  
Fibrinolytic Therapy ◽  
Mesothelial Cells ◽  
Plasminogen Activator Inhibitor 1 ◽  
Mesenchymal Transition ◽  
Pleural Injury ◽  
Activator Inhibitor ◽  
Intrapleural Administration

Recent studies have shed new light on the role of the fibrinolytic system in the pathogenesis of pleural organization, including the mechanisms by which the system regulates mesenchymal transition of mesothelial cells and how that process affects outcomes of pleural injury. The key contribution of plasminogen activator inhibitor-1 to the outcomes of pleural injury is now better understood as is its role in the regulation of intrapleural fibrinolytic therapy. In addition, the mechanisms by which fibrinolysins are processed after intrapleural administration have now been elucidated, informing new candidate diagnostics and therapeutics for pleural loculation and failed drainage. The emergence of new potential interventional targets offers the potential for the development of new and more effective therapeutic candidates.

Role of α2Plasmin Inhibitor in Fibrinolytic Therapy by Urokinase and the Optimal Urokinase Dosage

1979 ◽  
Author(s):  
S. Hayashi ◽  
K. Yamada
Keyword(s):  
Correlation Coefficients ◽  
Fibrinolytic Therapy ◽  
Optimal Dosage ◽  
Clinical Role ◽  
Fibrin Plate ◽  
Plasmin Inhibitors ◽  
Thrombotic Diseases ◽  
Plasmin Inhibitor ◽  
Different Doses

A novel plasmin inhibitor, namely α2plasmin inhibitor (α2PI), was found to be more efficient than other plasmin inhibitors but its clinical role in fibrinolytic therapy by urokinase (UK) was not examined. We injected UK into 9 patients with thrombotic diseases at several different doses (2-180×l04 IU/day) in order to estimate the optimal dosage inducing fibrinolysis, ahd to evaluate the role of α2PI in fibrinolysis during UK administration. The correlation coefficients(CE) between UK/day and α2PI, plasminogen (PIg), ulantitrypsin (UIAT) and α2macroglobulin(α2MC) were-0.75, -0.54, 0.39 and -0.37, respectively. Above50×104 of UK/day, the α2PI level fell below 60%, and above 150×10 4 IU of UK/day it fell below 30%. The CE between lysis area on fibrin plate (FPL) and α2PI, α2AT, α2MC, UK/day and PIg were -0.69, 0.51, -0.31, 0.30 and -0.26, respectively. When the level of α2PI fell below 60%, EPL was observed in 13 of 20 samples (65%) , whereas above 60% of α2PI it was observed in only 4 of 35 samples (11%). The above results suggest that α2PI is most important in regUlating fibrinolysis during UK administration and about 50xl0 4IU/day of UK should be infused in order to lower the level of α2PI to below 60%, so inducing prominent fibrinolysis.

Sign in / Sign up

Export Citation Format

Share Document